Spero Therapeutics (SPRO)
(Delayed Data from NSDQ)
$1.30 USD
+0.01 (0.78%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.27 -0.03 (-2.31%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
SPRO 1.30 +0.01(0.78%)
Will SPRO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for SPRO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SPRO
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
SPRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
Other News for SPRO
Promising Clinical Developments Underpin Buy Rating for Spero Therapeutics
Spero Therapeutics announces publication of SPR719 trial data
Spero Therapeutics to Present at Upcoming September Investor Conferences
Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript
Spero Therapeutics (SPRO) was upgraded to a Buy Rating at TD Cowen